Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Bremer

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Oncoimmunology|September 18, 2018
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpointIris Koopmans, Djoke Hendriks, Douwe F Samplonius, et al.
Oncoimmunology|September 14, 2016
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis inductionDjoke Hendriks, Yuan He, Iris Koopmans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 25, 2008
Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion proteinEdwin Bremer, Gooitzen M van Dam, Marco de Bruyn, et al.
Frontiers in Pharmacology|July 11, 2025
Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagyLisanne Koll, Harm Jan Lourens, Glenn Marsman, et al.
Theranostics|February 24, 2022
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonismJuliane Medler, Kirstin Kucka, Vinicio Melo, et al.
Communications Biology|March 7, 2023
The DNA damage response pathway regulates the expression of the immune checkpoint CD47Lucy Ghantous, Yael Volman, Ruth Hefez, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 28, 2008
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cellsEdwin Bremer, Marco de Bruyn, Douwe F Samplonius, et al.
Biomedicines|January 21, 2022
Galectin-9 Triggers Neutrophil-Mediated Anticancer ImmunityNatasha Ustyanovska Avtenyuk, Ghizlane Choukrani, Emanuele Ammatuna, et al.
Biomedicines|May 28, 2022
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell LymphomaJimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, et al.
Frontiers in Immunology|November 7, 2022
Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survivalMartijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Oncoimmunology|September 18, 2018
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpointIris Koopmans, Djoke Hendriks, Douwe F Samplonius, et al.
Oncoimmunology|September 14, 2016
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis inductionDjoke Hendriks, Yuan He, Iris Koopmans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 25, 2008
Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion proteinEdwin Bremer, Gooitzen M van Dam, Marco de Bruyn, et al.
Frontiers in Pharmacology|July 11, 2025
Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagyLisanne Koll, Harm Jan Lourens, Glenn Marsman, et al.
Theranostics|February 24, 2022
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonismJuliane Medler, Kirstin Kucka, Vinicio Melo, et al.
Communications Biology|March 7, 2023
The DNA damage response pathway regulates the expression of the immune checkpoint CD47Lucy Ghantous, Yael Volman, Ruth Hefez, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 28, 2008
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cellsEdwin Bremer, Marco de Bruyn, Douwe F Samplonius, et al.
Biomedicines|January 21, 2022
Galectin-9 Triggers Neutrophil-Mediated Anticancer ImmunityNatasha Ustyanovska Avtenyuk, Ghizlane Choukrani, Emanuele Ammatuna, et al.
Biomedicines|May 28, 2022
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell LymphomaJimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, et al.
Frontiers in Immunology|November 7, 2022
Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survivalMartijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, et al.
Pageof 10